]>
IRCT20191216045755N1 IRCT 2019-12-27 Iran University of Medical Sciences The Evaluation Of Adding Erythropoietin In Cardioplegic Solution On The Time Required for Mechanical Ventilation and The Need for Inotrop In Pattions After CABG In Rasool-e-Akram Hospital The Evaluation Of Adding Erythropoietin In Cardioplegic Solution On The Time Required for Mechanical Ventilation and The Need for Inotrop In Pattions After CABG In Rasool-e-Akram Hospital In The First 6 Months of 1398 2019-09-23 anticipated 80 Complete https://irct.ir/trial/44293 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: According to inclusion and exclusion criteria, patients are admitted to the hospital within the specified interval. Then, patients are divided into two intervention and control groups using simple random method and random number table. Patients are identified and then each patient is assigned a code, and patients are selected by pointing the finger or the tip of the pen or closing their eyes according to the code, one of which is divided into the intervention and comparison groups. 3 Coronary ischemic patients. Intervention 1: Intervention group:Erythropoietin is a precursor of erythrocytes (erythrocytes) which in the intravenous form has no side effects except mild nausea and hypertension and also has a protective effect against cardiac ischemia. Anesthesia (given as premedication midazolam .015mg / kg and Fentanyl 2_10macro / kg ketamin 50mg infusion and given as induction of neonatal 2_5mg / kg and pawlone 0.1mg / kg in patients with primary creatinine above 1.5 instead of Pavlovian Atracoril) Specific ionic and preservative concentrations and compounds in accordance with the national protocol of 15 cc per kg of bad weight It is injected over 3 minutes at 4 ° C with a pressure of 50-50 mm Hg through the aortic root to achieve complete cardiac arrest. In this group, a vial of erythropoietin manufactured by Synagen. 4,000 units are added intravenously to the cardioplegia solution, which is injected with the other compounds into the cardiovascular system. Intervention 2: Control group: No extra work. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is I haven't consulted
public Behdad Maadani
Mansoori Ave, Niayesh Ave ,Sattarkhan Town
Tehran Iran (Islamic Republic of) 8874113911 +98 21 8861 0120 behdad_madaani@hotmail.com Iran University of Medical Sciences scientific Behdad Madaani
Mansoori Ave, Niayesh Ave ,Sattarkhan Town
Tehran Iran (Islamic Republic of) 8874113911 +98 21 8861 0120 behdad_madaani@hotmail.com Iran University of Medical Sciences Iran (Islamic Republic of) Patients with ischemic coronary artery disease who are not eligible for angiographic treatment and who are candidates for surgery for coronary artery disease (CABG) 2-Patients with ischemic coronary artery disease aged 40 to 80 years 40 years 80 years Both 1- Patients undergoing heart replacement surgery under open heart surgery                               2- Anatomical heart disease undergoing open heart surgery 3- Patients with coronary artery disease who have cardiac-respiratory arrest under open heart surgery I25 Chronic ischemic heart disease Treatment - Drugs N/A Intervention group:Erythropoietin is a precursor of erythrocytes (erythrocytes) which in the intravenous form has no side effects except mild nausea and hypertension and also has a protective effect against cardiac ischemia. Anesthesia (given as premedication midazolam .015mg / kg and Fentanyl 2_10macro / kg ketamin 50mg infusion and given as induction of neonatal 2_5mg / kg and pawlone 0.1mg / kg in patients with primary creatinine above 1.5 instead of Pavlovian Atracoril) Specific ionic and preservative concentrations and compounds in accordance with the national protocol of 15 cc per kg of bad weight It is injected over 3 minutes at 4 ° C with a pressure of 50-50 mm Hg through the aortic root to achieve complete cardiac arrest. In this group, a vial of erythropoietin manufactured by Synagen. 4,000 units are added intravenously to the cardioplegia solution, which is injected with the other compounds into the cardiovascular system. Control group: No extra work The presence or absence of erythropoietin in the cardioplegia solution. Timepoint: After surgery. Method of measurement: Researcher Information. Total postoperative hospital stay. Timepoint: After Surgery. Method of measurement: Based on the case. Duration of ICU admission. Timepoint: Operation time until leaving ICU. Method of measurement: Based on the case. The dose of inotropes required after surgery. Timepoint: After Surgery. Method of measurement: Based on the case. Iran University of Medical Sciences Approved 2019-08-27 Iran University of Medical Sciences Mansoori Ave, Niayesh Ave ,Sattarkhan Town Tehran Tehran Iran (Islamic Republic of)